Glioblastoma — frontier options in Michigan
19 open options
- TRIALPHASE2RECRUITING
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
ACT001 — 20 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 127 sites
- TRIALPHASE2RECRUITING
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging · Fluciclovine F18 · Gadolinium-Chelate — 18 sites
- TRIALPHASE2NOT_YET_RECRUITING
Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Patients Diagnosed With a Glioma
Minocycline 200mg/day · [18F]FETrp PET/CT — 1 site
- TRIALPHASE2RECRUITING
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
silevertinib in combination with temozolomide · temozolomide (TMZ) — 25 sites
- TRIALPHASE2RECRUITING
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
PEP-CMV · Temozolomide · Tetanus Diphtheria Vaccine — 13 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LCB84 · Anti-PD-1 monoclonal antibody — 8 sites
- TRIALPHASE1RECRUITING
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Eflornithine (Dose Level 1) · Eflornithine (Dose Level 2) · Eflornithine (Dose Level -1) — 8 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Ulixertinib (BVD-523) — 26 sites
- TRIALEARLY_PHASE1NOT_YET_RECRUITING
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
[64Cu]CM500 · [68Ga]CM500 · PET/MR — 3 sites
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 57 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide · Lomustine · Regorafenib — 63 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
DCVax-L — 27 sites
- TRIALPHASE1RECRUITING
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
PF-07799544 · PF-07799933 — 83 sites
- TRIALPHASE3RECRUITING
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
safusidenib · Placebo — 57 sites
- TRIALPHASE1RECRUITING
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
ONC206 · Standard of Care Radiation Therapy · Optional Proton (1H) MR spectroscopy (MRS) — 7 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
BAY 3713372 — 60 sites
- TRIALPHASE1RECRUITING
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS) — 1 site
- TRIALPHASE2RECRUITING
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Ribociclib · Everolimus · Temozolomide (TMZ) — 20 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.